# A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

> **NCT04919512** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 163 (actual)

## Conditions studied

- Urinary Bladder Neoplasms

## Interventions

- **DRUG:** TAR-200
- **BIOLOGICAL:** Cetrelimab

## Key facts

- **NCT ID:** NCT04919512
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-07
- **Primary completion:** 2025-02-04
- **Final completion:** 2026-03-31
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04919512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04919512, "A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04919512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*